32
Participants
Start Date
July 31, 2015
Primary Completion Date
August 31, 2016
Study Completion Date
January 31, 2017
ALLN-177 low dose
ALLN-177 1,500 units (1 capsule)/meal PO 3 times per day
ALLN-177 mid dose
ALLN-177 3,000 units (2 capsules)/meal PO 3 times per day
ALLN-177 high dose
ALLN-177 7,500 units (5 capsules)/meal PO 3 times per day
Placebo
Placebo: 1, 2 or 5 capsules with meals PO 3 times per day
New York University - Division Of Nephrology, New York
North Shore Long Island Jewish Health System/The Arthur Miller Institute for Urology, Lake Success
Brooklyn Urology Research Group, Brooklyn
Anne Arundel Urology, Annapolis
Urology of Virginia, Virginia Beach
Atlantic Urological Associates, Daytona Beach
Mayo Clinic - Nephrology And Hypertension, Jacksonville
Cleveland Clinic-Urology, Cleveland
The Urology Group, Cincinnati
IU Health Physicians Urology, Indianapolis
Mayo Clinic, Rochester
Northwestern Feinberg School Of Medicine - Urology Department, Chicago
UT Southwestern Medical Center - Urology, Dallas
Tower Urology, Los Angeles
Massachusetts General Hospital, Boston
Omega Clinical Research, Warwick
Lead Sponsor
Allena Pharmaceuticals
INDUSTRY